Plos Biology: The regulatory mechanism that inhibits cholesterol synthase and accelerates the growth of renal cell carcinoma

It is generally believed that high serum cholesterol will cause tumor deterioration and complications in cancer patients, and affect the prognosis of cancer patients, while low serum cholesterol is beneficial to the recovery of cancer patients

Recently, the research of the Mi Shengli research group of Shenzhen International Graduate School proved that although the inhibition of cholesterol synthesis rate-limiting enzyme HMGCR in renal cancer cells leads to a decrease in serum cholesterol in tumor-bearing mouse models, glycolysis in RCC tumor tissues is enhanced and lactic acid accumulates.

3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the main rate-limiting enzyme in the cholesterol synthesis pathway.

This study proved that the degree of inhibition of HMGCR is positively correlated with tumor glycolysis and RCC growth

Related results were recently published in "Public Science Library Biology" under the title "HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma" (HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma) (Plos Biology) on

Paper link:

https://journals.